Augmenting ultrasound for continuous glucose monitoring via a wearable acoustically readable microneedle patch
Clinical Snapshot
PICO Framework
| P — Population | Animal models (mice) with potential application to humans requiring continuous glucose monitoring |
| I — Intervention | Wearable acoustically readable microneedle patch (ARMPatch) with glucose-responsive hydrogel |
| C — Comparator | Current enzymatic continuous glucose monitoring systems |
| O — Outcomes | Glucose monitoring accuracy, stability (up to 56 days), response time (30-60 minutes), millimolar resolution, correlation with glucose variations |
Bottom Line
This preclinical study presents an innovative enzyme-free continuous glucose monitoring system using ultrasound-readable microneedle patches. The ARMPatch demonstrated 56-day stability and millimolar glucose resolution in animal models, potentially addressing current CGM limitations of cost and durability. However, the 30-60 minute response time is slower than existing systems, and the technology remains in early development stages. While promising for future diabetes management, clinical translation requires human trials to establish safety, efficacy, and regulatory approval. Australian clinicians should view this as an interesting technological advancement that may eventually complement existing CGM options, but current diabetes management should continue with established, TGA-approved devices.
Key Findings
P Value: Not reported
Effect Size: Millimolar resolution glucose detection
Primary Outcome: Successful glucose monitoring with reversible correlation between microneedle swelling and glucose variations
Nnt Or Sensitivity: Response time: 30-60 minutes, stability: 56 days, 7-day continuous monitoring demonstrated
Confidence Interval: Not reported
Clinical Application
Requires standard ultrasound equipment; may be feasible in clinical settings with appropriate training Would require TGA approval for therapeutic use; potential PBS listing considerations for diabetes management; alignment with RACGP diabetes care guidelines pending clinical validation Currently limited to research applications; potential future use in diabetes patients requiring continuous glucose monitoring
Abstract
Continuous glucose monitoring (CGM) represents substantial advancement, yet poses a challenge in wearable health care development. Current enzymatic CGM faces limitations in stability, cost, and durability. We introduce an enzyme-free, wearable acoustically readable microneedle patch (ARMPatch) composed of glucose-responsive hydrogel. Positioned between a standard ultrasound probe and the skin, ARMPatch acts as an acoustic interface enabling CGM using conventional ultrasound. Its hydrogel microneedles minimally penetrate the epidermis, allowing interstitial fluid to trigger variable swelling of the microneedles in response to glucose fluctuations. ARMPatch delivers stable and selective glucose readings for up to 56 days. Glucose variations with millimolar resolution are obtained via ultrasound within a response time of 30 to 60 minutes. In vivo CGM in animal models for 7 days reveals a reversible correlation between microneedle swelling and glucose variations. Acting as "accessory" for standard ultrasound probes, this approach offers a minimally invasive, cost-effective, and long-lasting solution to non-enzymatic CGM, expanding the utility of ultrasound in wearable biosensing.
References
- 1.Zhang, W., Xu, J., Li, X., Jang, Y., Liu, Q., Ma, W., Luo, G., Ma, M., Wang, Q., He, Y., Yuan, Q., Jeong, J. W., Meng, L., & Su, Z. (2026). Augmenting ultrasound for continuous glucose monitoring via a wearable acoustically readable microneedle patch. Science Advances. https://doi.org/10.1126/sciadv.aec3209
Related Research
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
Journal of chemical information and modeling
A Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug-Hormone Receptor Interactions with Structure-Aware Validation
28 July 2026
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Differential effects of hormone therapy formulations on Parkinson's disease risk: a systematic review and meta-analysis
23 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service